Accessibility Menu
Fractyl Health logo

Fractyl Health(NASDAQ) GUTS

Current Price$0.75
Market Cap$120.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-94%
5 YearN/A
1 Year-59%
1 Month-13%
Fractyl Health last closing stock price
MetricPriceDate
Last closeUSD 0.762026-07-22
Fractyl Health stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.7%USD 0.912026-07-15
1 month-12.77%USD 0.872026-06-22
3 month+30.46%USD 0.582026-04-23
Year to date-65.55%USD 2.202025-12-31
1 year-59.25%USD 1.862025-07-22
Since inception-94.1%USD 12.852024-02-02

Fractyl Health Financials at a Glance

Market Cap

$120.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$108.00M

EPS (TTM)

-$1.50

P/E Ratio

-0.50

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$0.75

Volume

1,224,208.391

Open

$0.76

Previous Close

$0.76

Daily Range

$0.74 - $0.78

52-Week Range

$0.38 - $2.45

Estimated Earnings Date

Aug 11, 2026

GUTS News

Financial Technologies - binary code background with dollar banknotes

How to Invest Like Peter Thiel

Jon QuastMay 1, 2026
Foolcom-Featured.png

Fractyl Health Posts 62% Wider Q2 Loss

Motley Fool Markets TeamAug 12, 2025

GUTS: Motley Fool Moneyball Superscore

33

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fractyl Health

Fractyl Health develops therapies for people with type 2 diabetes and obesity. Its main products aim to improve blood sugar control and weight management. These therapies target the digestive system and pancreas to address disease causes, not just symptoms.

Products and Services

  • Revita DMR System: Outpatient procedure to remodel the duodenum, aiming to improve blood sugar and weight control. (0% of revenue in 2025; all revenue paused)
  • Rejuva Gene Therapy: Single-dose gene therapy targeting pancreatic cells for long-term diabetes and obesity management. (0% of revenue in 2025)
  • Clinical Research: Conducts studies and trials for metabolic disease therapies, focusing on type 2 diabetes and obesity.
  • Regulatory Submissions: Manages applications and compliance for new therapies in the U.S. and abroad.

Growth and Expansion

  • Launched Revita clinical studies in the U.S. and Europe since 2021.
  • Signed a letter of intent with Everself for commercialization partnerships in 2025.
  • Submitted clinical trial applications for Rejuva in the Netherlands and Australia in 2025.
  • Paused commercial pilot in Germany in 2025 to focus on obesity and gene therapy programs.

What Makes Fractyl Health Stand Out

Fractyl Health targets the underlying causes of metabolic diseases, not just symptoms. Its therapies are designed for single administration, aiming for long-term effects. The company holds a broad patent portfolio and focuses on partnerships with specialized medical centers.

Five Things You Need to Know

  • Revenue was $0 in QQ3 2025, down 100% from QQ3 2024.
  • Operating loss was $23 million in QQ3 2025, a 4.6% improvement from QQ3 2024.
  • Cash and equivalents were $103 million in QQ3 2025, down 15.3% from QQ3 2024.
  • Net loss was $46 million in QQ3 2025, nearly double from QQ3 2024.

Bottom Line

Fractyl Health has shifted from early commercial efforts to focus on clinical development and regulatory milestones. The company’s future depends on successful trials and securing additional funding.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

100

CEO

Harith Rajagopalan, MD, PhD

Website

www.fractyl.com

Headquarters

Burlington, MA 01803, US

GUTS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-4573.89%

Return on Capital

-136.16%

Return on Assets

-108.67%

Earnings Yield

-2.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$120.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

158.65M

Volume

1.22M

Avg. Volume

2.02M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$92.88M

EBITDA

-$106.88M

Operating Cash Flow

-$87.73M

Capital Expenditure

-$109.00K

Free Cash Flow

-$87.84M

Cash & ST Invst.

$63.17M

Total Debt

$60.82M

Fractyl Health Performance Analysis

Fractyl Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 120,000N/A
20242024-12-31USD 93,000-22.5%
20252025-12-31USD 0N/A
Fractyl Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Fractyl Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3419.6%
20232023-12-31USD -21.111479.1%
20242024-12-31USD -1.44-93.2%
20252025-12-31USD -1.8628.7%
Fractyl Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-16.3%
Q32025-09-30-24.6%
Q42025-12-3118.3%
Q12026-03-31120.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$120.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.20M

N/A

Employees

100

N/A

Net Income

$9.22M

+138.8%

EBITDA

$9.50M

+140.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$63.17M

+50.0%

Total Debt

$60.82M

-1.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$55.68M

-1.3%

Short Term Debt

$5.14M

+3.0%

Return on Assets

-1.09%

N/A

Return on Invested Capital

-1.11%

N/A

Free Cash Flow

-$22.48M

+11.9%

Operating Cash Flow

-$22.48M

+10.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RPTXRepare Therapeutics Inc.
$2.65+0.00%
ADVMAdverum Biotechnologies, Inc.
$4.36+0.00%
DTILPrecision BioSciences, Inc.
$7.26-0.89%
BMEABiomea Fusion, Inc.
$1.27-1.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.88-0.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.16+0.05%
HBANHuntington Bancshares
$17.38-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$37.03+0.08%

Questions About GUTS

What is the current price of Fractyl Health?

Fractyl Health is trading at $0.75 per share.

What is the 52-week range for Fractyl Health?

Over the past 52 weeks, Fractyl Health has traded between $0.38 and $2.45.

How much debt does Fractyl Health have?

As of the most recent reporting period, Fractyl Health reported total debt of $60.82M.

How much cash does Fractyl Health have on hand?

Fractyl Health reported $63.17M in cash and cash equivalents in its most recent financial results.

What is Fractyl Health’s dividend yield?

Fractyl Health does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services